Edgewise Therapeutics, Inc. - Common Stock (EWTX)

CUSIP: 28036F105

Q3 2025 13F Holders as of 30 Sep 2025

Security type / class
Equity / Common Stock
Total 13F shares
111,964,035
Total 13F value
$1,816,272,411
Holder snapshot 6 visible 7 signals
Share change
-6,779,965
Put/Call ratio
53%
SEC-reported price per share
$16.22
Number of holders
172
Value change
-$102,066,033
Number of buys
75
Open additional details 1 more signal available
Number of sells
85
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
107,555,564

Security key

28036F105

Report period

Q3 2025

Institutions

172

Top holders

10

EWTX full security history Ownership snapshot Full 13F holder table Newer quarter: Q4 2025 Previous quarter: Q2 2025 Edgewise Therapeutics, Inc. SEC filings Edgewise Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of EWTX - Edgewise Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G 3/4/5 13F Lead comparable stake: 14% 13D/G row: ORBIMED ADVISORS LLC Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 14%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership Top 5
ORBIMED ADVISORS LLC 14%
RA CAPITAL MANAGEMENT, L.P. 9.9%
BAKER BROS. ADVISORS LP 6.9%
BlackRock, Inc. 5.5%
PERCEPTIVE ADVISORS LLC 4.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ORBIMED ADVISORS LLC
13D/G 3/4/5 13F
Director, 10%+ Owner · Company
13D/G 3/4/5 13F
14%
$234,894,152
15,252,867 shares
 $0 09 May 2025
RA CAPITAL MANAGEMENT, L.P.
13D/G 13F
Company
13D/G 13F
9.9%
$169,149,248
10,428,437 shares
 $0 30 Sep 2025
BAKER BROS. ADVISORS LP
13F 13D/G
Company
13F 13D/G
6.9%
from 13D/G
$95,780,873
7,305,940 shares
 — 30 Jun 2025
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
5.5%
from 13D/G
$88,899,513
6,781,046 shares
 — 30 Jun 2025
PERCEPTIVE ADVISORS LLC
13F 13D/G
Company
13F 13D/G
4.4%
from 13D/G
$60,829,731
4,639,949 shares
 — 30 Jun 2025
Paradigm Biocapital Advisors LP
13F
Company
13F
5.7%
$80,526,130
6,142,344 shares
 — 30 Jun 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
172
Shares
111,964,035
Rows available
172
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders
177
Q3 2025 holders
172
Holder diff
-5
Investor Q2 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2025 value Q3 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .